THERAPY DOSSIER · th-f86c4257c428

Ryanodine receptor and inositol triphosphate receptor blockers modulating intra-axonal calcium stores

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24395428 ↗2014Reported benefit

Axoplasmic reticulum Ca(2+) release causes secondary degeneration of spinal axons.

MouseSpinal cord injuryUnspecifiedC57BL/6, including transgenic reporter lines and a gain-of-function ryanodine receptor 2 mutant line

Model: Two-photon laser-induced injury of myelinated spinal white matter axons, imaged live

Reducing calcium release from ryanodine and inositol triphosphate receptor mediated axonal stores significantly decreased axonal dieback and bystander injury, whereas a gain-of-function ryanodine receptor 2 mutation or pharmacological promotion of store release worsened both.

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…